# RESEARCH



# Factors to consider during anesthesia in patients undergoing preemptive kidney transplantation: a propensity-score matched analysis

Jeayoun Kim<sup>1†</sup>, Kyo Won Lee<sup>2†</sup>, Keoungah Kim<sup>3</sup>, Hyeryung Kang<sup>1</sup>, Jaehun Yang<sup>4</sup>, Jae Berm Park<sup>2</sup> and Gaabsoo Kim<sup>1\*</sup>

# Abstract

**Background** International guidelines have recommended preemptive kidney transplantation (KT) as the preferred approach, advocating for transplantation before the initiation of dialysis. This approach is advantageous for graft and patient survival by avoiding dialysis-related complications. However, recipients of preemptive KT may undergo anesthesia without the opportunity to optimize volume status or correct metabolic disturbances associated with end-stage renal disease. In these regard, we aimed to investigate the anesthetic events that occur more frequently during preemptive KT compared to nonpreemptive KT.

**Methods** This is a single-center retrospective study. Of the 672 patients who underwent Living donor KT (LDKT), 388 of 519 who underwent nonpreemptive KT were matched with 153 of 153 who underwent preemptive KT using propensity score based on preoperative covariates. The primary outcome was intraoperative hypotension defined as area under the threshold (AUT), with a threshold set at a mean arterial blood pressure below 70 mmHg. The secondary outcomes were intraoperative metabolic acidosis estimated by base excess and serum bicarbonate, electrolyte imbalance, the use of inotropes or vasopressors, intraoperative transfusion, immediate graft function evaluated by the nadir creatinine, and re-operation due to bleeding.

**Results** After propensity score matching, we analyzed 388 and 153 patients in non-preemptive and preemptive groups. The multivariable analysis revealed the AUT of the preemptive group to be significantly greater than that of the nonpreemptive group (mean  $\pm$  standard deviation, 29.7 $\pm$ 61.5 and 14.5 $\pm$ 37.7, respectively, *P*=0.007). Metabolic acidosis was more severe in the preemptive group compared to the nonpreemptive group. The differences in the nadir creatinine value and times to nadir creatinine were statistically significant, but clinically insignificant.

**Conclusion** Intraoperative hypotension and metabolic acidosis occurred more frequently in the preemptive group during LDKT. These findings highlight the need for anesthesiologists to be prepared and vigilant in managing these events during surgery.

<sup>†</sup>Jeayoun Kim and Kyo Won Lee contributed equally to this work.

\*Correspondence: Gaabsoo Kim gskim@skku.edu Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/A.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Keywords** End-stage renal disease, Intraoperative hypotension, Living donor kidney transplantation, Metabolic acidosis, Preemptive kidney transplantation

## Background

Kidney transplantation (KT) is an established treatment for end-stage renal disease (ESRD) [1]. Recently, international guidelines have recommended preemptive KT, which involves performing the transplantation before initiating dialysis [2, 3]. This approach offers several advantages, including improved graft function and patient survival by avoiding dialysis-related complications such as cardiovascular disease and infection [4–10]. Additionally, preemptive KT has been shown to offer significant benefits in terms of patient welfare [11, 12] and societal cost-saving [13, 14].

Patients undergoing preemptive KT may encounter specific challenges related to ESRD due to the relatively shorter transition period from ESRD to surgery. These challenges encompass imbalances in volume status and metabolic disturbances associated with acid/base and electrolyte levels, such as hyperkalemia, calcium, and phosphate disorders. Additionally, ESRD patients are at an increased risk for perioperative bleeding due to impaired platelet function and platelet-vessel wall interactions caused by the accumulation of uremic toxins [15–18]. Unfortunately, these issues often remain unresolved at the time of surgery.

However, there is a paucity of studies assessing the potential risks during anesthesia in preemptive KT patients. Therefore, we planned to investigate the anesthetic events that occur when patients were undergoing preemptive KT and determine which aspects require further attention. We conducted a retrospective cohort study to test our primary hypothesis that the extent and duration of intraoperative hypotension would be greater in the preemptive group compared to the nonpreemptive group.

## Methods

Assessed for eligability (n = 1,168) Adult KT

Enrollment (n = 674) LDKT

## Study design

The present study was a single-center, retrospective cohort study. The Institutional Review Board of Samsung Medical Center approved this study and waived the requirement for written informed consent (SMC 2018–10-147–001). A total of 1,168 adult recipients, who underwent KT between April 2010 and October 2018

Excluded (n = 2) intraoperative blood pressure had not been digitized

preemptive group (n = 153)



non-preemptive group (n = 519)

45 secondary KT

Fig. 1 Flow diagram for study enrollment and grouping

at Samsung Medical Center, was the initially screened cohort. Among these recipients, 494 recipients who underwent deceased donor KT (n=494) and with missing digitized data on intraoperative blood pressure (n=2) were excluded. The remaining 672 recipients who underwent living donor KT (LDKT) were analyzed in the present study, who were divided into the nonpreemptive and preemptive groups (Fig. 1).

### **Data collection**

Data were obtained from the electronic medical records or a KT database (prospectively collected) and were anonymized/de-identified before analysis. Baseline mean arterial pressure (MAP) was defined as the average of preoperative MAP values measured in the ward noninvasively until the patient was moved to the operating room (maximum of 10 recordings). Intraoperative MAP was recorded every five minutes automatically. We chose the invasive blood pressure values if both invasive and noninvasive blood pressure measurements were available; however, noninvasive blood pressure values were used if the invasive blood pressure could not be relied on due to artifacts. When MAP was not recorded, the MAP was calculated using the systolic and diastolic arterial pressure (SAP and DAP, respectively) according to the following formula:  $MAP = DAP + 1/3 \times (SAP - DAP)$ . Preoperative echocardiographic parameters were collected and used to evaluate the presence of uremic cardiomyopathy which is characterized by ventricular dysfunction and hypertrophy [19]. Left ventricular diastolic dysfunction (LVDD) was assessed according to the clinical comorbidities and echocardiographic findings [20-22]. We classified the patients with ischemic heart disease (IHD), clinical diagnosis of congestive heart failure (CHF), pathologic left ventricular hypertrophy (LVH), or left ventricular ejection fraction < 50% as having LVDD. We defined the cutoff values for LVH as left ventricular mass index > 115 g/m<sup>2</sup> in men and > 95 g/m<sup>2</sup> in women [23]. The modality and duration of renal replacement therapy, redo-KT, time from the last dialysis to KT in the non-preemptive group were also investigated.

Intraoperative arterial level of bicarbonate, base excess, and serum electrolytes (i.e., sodium, potassium, and calcium) were collected from the arterial blood gas analysis which was carried out immediately after induction. Postoperative nadir creatinine (Cr) values (i.e., the lowest Cr level in blood tests conducted according to the postoperative protocol), estimated glomerular filtration rate (eGFR), and Cr clearance (CCl) were collected. Serum and urine Cr level was measured with the kinetic alkaline picrate method (Jaffe Method) and the time to attain nadir Cr was determined via retrospective chart review. The eGFR was calculated using the modification of diet in renal disease equation [24].

#### Outcomes

The primary outcome was intraoperative hypotension defined as the sum of the area under the threshold (AUT) on the blood pressure curve. Figure 2 represents AUT calculation. AUT was the area under 70 mmHg in the graph with the X-axis as time and the Y-axis as MAP, reflecting the duration and severity for which an individual's MAP was measured below 70 mmHg. The MAP threshold of 70 was determined according to our institutional protocol and previous meta-analysis on the effect of intraoperative hypotension on end-organ damage [25, 26]. We utilized blood pressure data obtained from the



Fig. 2 Scheme for calculating area under the threshold

time of surgical incision to graft reperfusion to compute AUT. This approach was implemented to mitigate the influence of various factors that could potentially affect blood pressure levels prior to surgical incision, including endotracheal intubation and positional changes.

Secondary outcomes were intraoperative use of inotropes (such as dopamine or dobutamine), vasopressors (such as norepinephrine or vasopressin), or red blood cell transfusion, total volume of crystalloid fluid and synthetic colloid, immediate graft function as defined by the postoperative nadir Cr value and maximum eGFR, time to achieve nadir Cr, and postoperative transfusion and bleeding which was defined as the need for re-exploration due to bleeding.

## Anesthesia management

Anesthetic management was performed according to a standardized institutional protocol. No premedication was administered. After the patients arrived at the operating room, standard monitors including a non-invasive blood pressure monitor, pulse oximetry, electrocardiogram, and bispectral index monitor (BIS, Aspect Medical Systems, Natick, MA, USA) were applied. After the intubation was performed, invasive blood pressure monitoring was performed via the right radial artery. An antibiotics-coated 7-Fr three-lumen catheter was placed in the right internal jugular vein and central venous pressure was monitored. Anesthesia was maintained using inhalational anesthetics, desflurane. The oesophageal Doppler probe (CardioQ; Deltex Medical, Irving, TX, USA) or FloTrac/Vigileo monitoring system (FloTrac/Vigileo version 3.02, Edwards Lifesciences, Irvine, CA, USA) was applied, which facilitated estimations of preload and afterload. Balanced crystalloid including Hartmann's solution (JW Pharmaceutical, Seoul, Korea) and Plasma solution A (CJ, Seoul, Korea) were primarily used as the maintenance fluid. Fluid infusion and vasoactive/inotropic drugs were adjusted to maintain MAP≥70 mmHg prior to graft reperfusion and  $\geq$  90 mmHg following graft reperfusion to improve graft perfusion based on the hemodynamic variables in the CardioQ and FloTrac/ Vigileo monitoring system. For patients with metabolic acidosis (base excess <-10 mmol/L) and hemodynamic instability despite the use of vasoactive/inotropic drugs, sodium bicarbonate was infused at the clinician's discretion. Intraoperatively, the target blood hemoglobin for allogeneic red blood cells was 7.0 g/dl.

## Statistical analysis

Statistical analysis was performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and R version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria) with the package matchIt. Continuous variables

were analyzed using the Wilcoxon rank-sum test or Student's t-test where appropriate and presented as median (interquartile range) or mean (standard deviation) values, respectively. Categorical variables were analyzed using the chi-squared or Fisher's exact test where appropriate and presented as numbers (%).

We performed propensity score matching using nearest-neighbor matching without replacement and a matching tolerance of 0.2 to balance baseline characteristics and avoid selection bias, which was triggered by a nonpreemptive:preemptive ratio of 3:1 maximally with the following seven covariates: age, sex, diabetes, hypertension, prescription of antihypertensive medications (Angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, or calcium channel block), and history of CHF and IHD. Successful matching was defined when standardized mean difference for matched variables were < 10% [27]. After matching, 388 of 519 in the nonpreemptive group were matched with 153 of 153 patients in the preemptive group (Fig. 1). the group comparison of patient characteristics and outcomes were conducted using an univariable generalized estimating equation (GEE). The association of potential risk factors with intraoperative hypotension defined by AUT was tested by GEE. Factors with a *p*-value of less than 0.1 in the univariable analysis and group were included in the multivariable analysis. We conducted Spearman's correlation analysis in the preemptive group to assess the correlation between metabolic acidosis and AUT. A *P*-value of less than 0.05 was considered to be statistically significant.

## Results

The comparison of demographic and clinical parameters between the preemptive group and the nonpreemptive group is shown in Table 1. Prior to propensity score matching, 45 recipient (8.7%) underwent redo-KT. Most patients (473/519, 91.1%) in the nonpreemptive group had received hemodialysis and the median (IQR) duration of renal replacement therapy was 6.1 (2, 34) months, with an average interval of 1.6 days between the last dialysis session and the surgery. The nonpreemptive group exhibited a higher frequency of diabetes and CHF compared to the preemptive group. Conversely, hypertension was more prevalent in the preemptive group. In the matched cohort, the standardized mean differences of all seven matched-covariates were reduced to values below 10%, indicating that an adequate balance was achieved between treatment groups. Echocardiographic parameters suggested that LVH and LVDD were more frequent in the nonpreemptive group compared to the preemptive group. The baseline MAP was not significantly different prior to

## Table 1 Patient characteristics

Characteristics	Entire population			Propensity-score matched population				
	Nonpreemptive (n=519)	Preemptive (n = 153)	SMD	P value*	Nonpreemptive (n = 388)	Preemptive (n = 153)	SMD	P value**
Age > 60 years	56 (10.8)	17 (11.1)	0.010	0.911	37 (9.5)	17 (11.1)	0.052	0.649
Body mass index, kg/m <sup>2</sup>	22.6 (20.4, 25.1)	22.8 (20.7, 25.3)	0.038	0.748	22.6 (20.3, 25.1)	22.8 (20.7, 25.3)	0.026	0.917
Female sex, n (%)	211 (40.7)	66 (43.1)	0.050	0.584	159 (41.0)	66 (43.1)	0.044	0.744
Diabetes, n (%)	156 (30.1)	32 (20.9)	0.211	0.027	92 (23.7)	32 (20.9)	0.067	0.406
Hypertension, n (%)	457 (88.1)	140 (91.5)	0.114	0.234	346 (89.2)	140 (91.5)	0.079	0.432
Antihypertensive medication, n (%)	407 (78.4)	138 (90.2)	0.328	0.001	339 (87.4)	138 (90.2)	0.090	0.430
Cerebrovascular disease, n (%)	16 (3.1)	3 (2.0)	0.072	0.587	11 (2.8)	3 (2.0)	0.057	0.534
Congestive heart failure, n (%)	22 (4.2)	0 (0)	0.298	0.010	0 (0.0)	0 (0)	N/A	N/A
lschemic heart disease, n (%)	29 (5.6)	8 (5.2)	0.016	0.864	18 (4.6)	8 (5.2)	0.027	0.652
Revised cardiac risk index, n (%)			0.232	0.060			0.066	0.930
0	410 (79.0)	134 (87.6)			331 (85.3)	134 (87.3)		
1	92 (17.7)	16 (10.5)			48 (12.4)	16 (10.5)		
2	17 (3.3)	3 (2.0)			9 (2.3)	3 (2.0)		
Echocardiographic parameters <sup>a</sup>								
LVEF, %	62 (57, 66)	63 (59, 67)	0.325	0.021	63 (58, 67)	63 (59, 67)	0.224	0.017
LVMI, g/m <sup>2</sup>	117.2 (99.3, 145.0)	100.9 (89.4, 128.5)	0.455	< 0.001	117.62 (99.9, 147.5)	100.9 (89.4, 128.5)	0.466	< 0.001
LAVI, ml/m <sup>2</sup>	39.3 (31.4, 48.9)	36 (29.8, 42.3)	0.363	0.006	39.75 (32, 48.8)	36 (29.8, 42.3)	0.364	< 0.001
E/A ratio	0.94 (0.71, 1.2)	0.92 (0.74, 1.32)	0.109	0.334	0.95 (0.7, 1.2)	0.92 (0.74, 1.32)	0.085	0.290
Deceleration time, m/sec	222 (193.8, 261.0)	225.6 (205.1, 252.3)	0.040	0.443	220.1 (192.1, 261.0)	225.6 (205.1, 252.3)	0.048	0.567
E', m/sec	0.07 (0.06, 0.08)	0.08 (0.06, 0.1)	0.325	< 0.001	0.07 (0.06, 0.09)	0.08 (0.06, 0.1)	0.239	0.005
E/E' ratio	10 (8, 13)	8.31 (6.6, 10.3)	0.619	< 0.001	9.95 (8.0, 12.4)	8.3 (6.6, 10.3)	0.592	< 0.001
TR velocity (m/sec)	2.4 (2.2, 2.6)	2.24 (2.1, 2.4)	0.529	< 0.001	2.4 (2.2, 2.7)	2.2 (2.1, 2.4)	0.554	< 0.001
Left ventricular hypertrophy, n (%)	300 (64.4)	56 (42.1)		< 0.001	227 (65.0)	56 (42.1)	0.473	< 0.001
Systolic dysfunction, n (%)			0.319	0.055			0.223	0.150
$LVEF \ge 60\%$	299 (64.2)	96 (71.6)			229 (59.0)	96 (52.7)		
$50\% \le LVEF < 60\%$	138 (29.6)	37 (27.6)			108 (27.8)	37 (24.2)		
$40\% \le LVEF < 50\%$	17 (3.6)	1 (0.7)			7 (1.8)	1 (0.7)		
LVEF < 40%	12 (2.6)	0 (0)			5 (1.3)	0 (0)		
Diastolic dysfunction, n (%) <sup>b</sup>			0.484	< 0.001			0.430	< 0.001
Indeterminate	50 (10.7)	5 (3.7)			121 (31.2)	44 (28.8)		
Grade 1	177 (38)	44 (32.6)			38 (9.8)	5 (3.3)		
Grade 2	92 (19.7)	18 (13.3)			72 (18.6)	18 (11.8)		
Grade 3	5 (1.1)	0 (0)			1 (0.3)	0 (0.0)		
Preoperative plasmapheresis for ABOi KT	93 (17.9)	25 (16.3)	0.042		66 (17)	25 (16.3)	0.018	0.858
Modality of renal replacement therapy, n (%)			N/A	N/A			N/A	N/A
Hemodialysis	473 (91.1)	0 (0)			351 (90.5)			
Peritoneal dialysis	46 (8.9)	0 (0)			37 (9.5)			
Duration of renal replacement therapy, months	6 (2, 34)	0 (0, 0)	N/A	N/A	5.03 (1.7, 29.0)		N/A	N/A
Operation time, min	183 (155, 213)	174 (151, 216)	0.093	0.405	184 (155, 213)	174 (151, 216)	0.097	0.422
Baseline Cr, mg/dL	7.7 (5.7, 10.2)	7.5 (6.4, 9.2)	0.089	0.980	8.1 (6, 10)	7.5 (6.4, 9.2)	0.081	0.295

Data are expressed as as mean ± standard deviation (SD), median (interquartile range), or as number (percentage)

SMD standardized mean difference, LV left ventricular, EF ejection fraction, LAVI left atrial volume index, E/A ratio E/A ratio of peak spectral transmitral flow velocities, E' peak early diastolic tissue velocity at the mitral annulus, TR tricuspid regurgitation, ABOi KT ABO incompatible kidney transplantation, Cr creatinine

\* P values were calculated using Mann–Whitney U test, student t-test, chi-square test, or Fisher's exact test

\*\* P values were calculated using generalized estimating equation

<sup>a</sup> 72 missing values for LVEF, 73 missing values for LVMI,76 values for LAVI, 97 missing values for E/A ratio, 102 missing values for deceleration time, 86 missing values for E', 97 missing values for E/C ratio, 249 missing values for TR velocity

<sup>b</sup> 71 missing values for diastolic dysfunction

matching, but after matching, a significant difference was observed between the two groups (99.2 mmHg and 102.0 mmHg, respectively, P < 0.0015).

## Anesthetic events

The anesthetic events that occurred during surgery are summarized in Table 2. The generalized estimating equation demonstrated that the mean AUTs was significantly higher in the preemptive group compared to the nonpreemptive group ( $29.7 \pm 61.0 \text{ vs. } 14.5 \pm 37.7$ , P = 0.002). This findings consisted in the multivariable analysis, which adjusted for the effect of baseline MBP and RCRI score (P = 0.007). Also, more inotropes and vasopressors were administered in the preemptive group (P < 0.001 and = 0.002, respectively).

Metabolic acidosis was severe in the preemptive group. Bicarbonate and base excess values in the non-preemptive were lower and the median (range) dose of intraoperative bicarbonate administered was higher compared to the nonpreemptive group (0 [0, 240] vs. 0 [0, 160], P=0.009). Finally, base excess values demonstrated low negative correlation with AUT in the preemptive group (Fig. 3).

## Immediate postoperative outcomes

The details of the immediate postoperative course following KT is summarized in Table 3.

The nadir Cr value in the nonpreemptive group was  $0.96 \pm 0.3$  mg/dL and that in the preemptive group was

 $0.90 \pm 0.34$  mg/dL (*P*=0.0237), while the times to nadir Cr in the nonpreemptive and preemptive groups were  $4.08 \pm 2.3$  and  $5.55 \pm 4.12$  days, respectively (*P*<0.0001); however, neither of these were clinically impressive, even though the differences were statistically significant. Operation time and postoperative bleeding were also not significantly different between the nonpreemptive and preemptive groups.

## Discussion

This study was designed based on the hypothesis that preemptive KT patients exhibit greater hemodynamic instability during anesthesia and experience worse postoperative graft function compared to nonpreemptive KT patients. In the preemptive group, the extent and duration of intraoperative hypotension were greater than the nonpreemptive group. Immediate postoperative graft function, as indicated by nadir Cr level and time to nadir Cr level demonstrated a clinically insignificant improvement in favor of the preemptive group compared to the nonpreemptive group.

In the present study, the preemptive group exhibited significantly greater duration and severity of intraoperative hypotension as measured by AUT, despite the nonpreemptive group showing a higher frequency of left ventricular hypertrophy, systolic and diastolic dysfunction. The observed significant of these findings remained after adjusting for baseline MAP in multivariable analysis. Our findings contrast with the results reported in a previous study that compared blood pressure at the

## Table 2 Intraoperative outcomes

	Nonpreemptive	Preemptive	<i>p</i> value	
	(n = 388)	( <i>n</i> = 153)		
Primary outcome				
AUT (< MAP 70 mmHg) <sup>a</sup>	14.5±37.7	29.7±61.0	0.002	
Secondary outcomes				
Inotropic use, n (%)	54 (13.9)	43 (28.1)	< 0.001	
Vasopressor use, n (%)	7 (1.8)	15 (9.8)	< 0.001	
Red blood cell transfusion, n (%)	18 (4.6)	17 (11.1)	0.007	
Total volume of crystalloid, L	3.1 (2.5, 3.6)	3.1 (2.6, 3.7)	0.127	
Total volume of synthetic colloid, L	0.2 (0, 0.5)	0.2 (0, 0.5)	0.675	
Initial blood gas analysis <sup>b</sup>				
Base excess, mmol/L	0.6 (-1.9, 2.9)	-7.4 (-10.1, -4.9)	< 0.001	
Serum bicarbonate, mmol/L	24.7 (22.5, 26.7)	18.1 (16.1, 19.9)	< 0.001	
Serum sodium level, mmol/L	136 (134, 138)	137 (135, 139)	< 0.001	
Serum potassium level, mmol/L	4.1 (3.6, 4.6)	4.1 (3.8, 4.6)	0.673	
Serum calcium level, mg/dL	1.0 (1.0, 1.1)	1.0 (1.0, 1.1)	0.914	
Sodium bicarbonate use, mEq	0 (0, 0)	0 (0, 0)	0.009	

<sup>a</sup> AUT (<MAP 70 mmHg), area under the threshold, with a threshold set at a mean arterial blood pressure below 70 mmHg

<sup>b</sup> Blood gas analysis was carried out immediately after induction



Fig. 3 Relationship between intraoperative base excess levels and area under the threshold (AUT) with a threshold set at a mean arterial blood pressure below 70 mmHg

#### Table 3 Immediate postoperative outcomes

	Nonpreemptive	Preemptive (n = 388)	p value (n = 153)
Nadir Creatinine (mg/dL)	$0.96 \pm 0.3$	$0.90 \pm 0.34$	0.024
Time to nadir Creatinine (day)	5.55±4.1	4.08±2.3	< 0.001
Maximum eGRF (mL/ min/1.73m <sup>2</sup> )	89.7±28.4	93.7±27.7	0.099
Maximum Cr clearance	114.7±49.4	$130 \pm 88.3$	0.050
Postoperative transfusion, n (%) <sup>a</sup>	85 (21.9)	45 (29.4)	0.082
Postoperative bleeding, n (%) <sup>b</sup>	5 (1.3)	1 (0.7)	0.528

Cr creatinine, eGFR estimated glomerular filtration rate

<sup>a</sup> Postoperative transfusion within 3 days

<sup>b</sup> Postoperative bleeding was defined when the recipient required

re-exploration because of bleeding

beginning, in the middle and end of the surgery [28]. We conducted comparative analysis between the two groups, examining the extent and duration of blood pressure below a specific threshold for blood pressure, which was AUT, utilizing blood pressure data measured at 5-min intervals during surgery. Since there is currently no established threshold for intraoperative hypotension, we used a MBP threshold of 70, based on a meta-analysis that identified a threshold associated with acute kidney injury [25]. Considering that not only the severity but also the duration of intraoperative hypotension has been

associated with postoperative end-organ damage [25], AUT may serve as more reliable predictors for post-KT outcomes compared to blood pressures measurements taken at specific time points. Therefore, our findings could be more robust and reliable compared to previous studies that reported insignificant difference regarding the intraoperative blood pressure between the two groups [28].

The observed differences in the extent and duration of hypotension, as measured by AUT, between the two groups may be attributed to differences in metabolic acidosis. In the nonpreemptive group, the majority of patients underwent dialysis the day before surgery (478/519, 92.1%), which resulted in a significantly favorable base-excess profile compared to the preemptive group. The preemptive group exhibited significantly lower levels of intraoperative base excess and bicarbonate compared to the nonpreemptive group, and base excess level demonstrated a weak negative correlation with AUT. Metabolic acidosis could lead to reduction in cardiac contractility and catecholamine efficiency, and decreased vascular responsiveness to inotropics and vasopressors through various mechanisms [29-35]. In this regard, more pronounced metabolic acidosis in the preemptive group might have contributed to the occurrence of intraoperative hypotension.

Several studies have reported favorable outcomes in preemptive KT, including higher rates of graft success and lower rates of delayed graft function and acute rejection [4–7, 28, 36, 37]. However, other studies have

suggested that the graft outcomes in the preemptive group are comparable to those in the nonpreemptive group [38–41]. In our study, despite the preemptive group experiencing a greater extent and duration of intraoperative hypotension, we observed statistically significant but clinically insignificant differences in the nadir Cr value and time to reach the nadir Cr level, favoring the preemptive group over the nonpreemptive group. Intraoperative hypotension has been associated with an increased risk of postoperative kidney injury, with studies indicating that prolonged exposure (10 min) to MAP below 80 mmHg and shorter exposure to MAP below 70 mmHg are associated with increased risks [25, 26]. Moreover, the extent of intraoperative hypotension has been reported to be an independent risk factor for slower graft function [42]. Given these findings, one might expect a more detrimental impact on graft function and recovery in the preemptive group, where the extent and duration of intraoperative hypotension were greater. However, our study only revealed clinically insignificant differences. This may be attributable to the fact that we analyzed blood pressure data before graft reperfusion and the anesthesiologists made efforts to maintain the blood pressure above a MAP of 100 mmHg after reperfusion to avoid renal hypoperfusion using appropriate fluids and medications until sufficient urine output was achieved [43].

This study has several limitations. Firstly, this study is a retrospective cohort study conducted at a single center. Therefore, the generalizability of our findings to other populations may be limited and causal inference between the preoperative dialysis and intraoperative blood pressure remains uncertain. Future prospective studies or randomized controlled trials are needed to confirm the results obtained in this study. Secondly, although there is standardized anesthesia protocol for LDKT, some anesthesiologists may have opted for their own anesthesia regimen, deviating from the standardized protocol, which may have led to differences in intraoperative blood pressure. Thirdly, while efforts were made to account for all potential variables influencing intraoperative hypotension, there may be unconsidered confounding factors that persist. Fourthly, propensity score-matching resulted in the exclusion of transplant recipients who were expected to be hemodynamically unstable or have poor outcomes. For instances, no recipients in the preemptive group had a history of CHF, leading to exclusion of 22 recipients of the nonpreemptive group with a history of CHF. This suggests a potential risk of skewing the results. Finally, the present study focused on intraoperative and short-term outcomes, and further research should investigate the long-term implications of preemptive KT.

## Conclusion

Intraoperative hypotension and metabolic acidosis occurred more frequently in the preemptive group during LDKT. Our findings highlight the need for anesthesiologists to be prepared and vigilant in managing these events during surgery.

#### Abbreviations

<b>NUT</b>	Area under the threshold
HF	Congestive heart failure
Îr	Creatinine
CL	Creatinine clearance
DAP	Diastolic arterial pressure
GFR	Estimated glomerular filtration rate
SRD	End-stage renal disease
HD	Ischemic heart disease
T	Kidney transplantation
DKT	Living-donor KT
VDD	Left ventricular diastolic dysfunction
VH	Left ventricular hypertrophy
ЛАР	Mean arterial pressure
AP	Systolic arterial pressure

#### Acknowledgements

Not applicable

#### Authors' contributions

Name: Jeayoun Kim. Contribution: This author helped data acquisition and analysis and write the manuscript. Name: Kyo Won Lee. Contribution: This author helped analyze the data and write the manuscript. Name: Keoun-gah Kim. Contribution: This author helped perform the study and write the manuscript. Name: Hyeryung Kang. Contribution: This author helped data acquisition and enroll the patient. Name: Jaehun Yang. Contribution: This author helped data interpretation. Name: Jae berm Park. Contribution: This author helped conception and study design. All authors reviewed the manuscript.

Funding

None.

#### Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

#### Declarations

#### Ethics approval and consent to participate

The present study was approved by the institutional review board of Samsung Medical Center and the need for informed consent was waived (approval no. SMC 2018–10-147–001).

All experiments were performed in accordance with Declaration of Helsinki.

#### **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare no competing interests.

#### Author details

<sup>1</sup>Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul 06351, Korea. <sup>2</sup>Department of Transplantation Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. <sup>3</sup>Department of Anesthesiology and Pain Medicine, School of Dentistry, Dankook University, Cheonan, Korea. <sup>4</sup>Department of Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. Received: 1 February 2023 Accepted: 15 July 2023 Published online: 05 August 2023

#### References

- 1. Kohei N, Sawada Y, Hirai T, Omoto K, Ishida H, Tanabe K. Influence of dialysis duration on the outcome of living kidney transplantation. Ther Apher Dial. 2014;18(5):481–8.
- Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, Hays R, Howard A, Jones E, Leichtman AB. Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/ Kidney Disease Outcomes Quality Initiative (NKF/KDOQI<sup>™</sup>) conference. Clin J Am Soc Nephrol. 2008;3(2):471–80.
- 3. Procurement O, Network T, Committee MA. Educational guidance on patient referral to kidney transplantation. 2019.
- Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, Kumar D, Oberbauer R, Pascual J, Pilmore HL. KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. 2020;104(4S1):S11–103.
- Andrews PA, Burnapp L. British Transplantation Society/Renal Association UK guidelines for living donor kidney transplantation 2018: Summary of updated guidance. Transplantation. 2018;102(7):e307.
- Knoll G, Cockfield S, Blydt-Hansen T, Baran D, Kiberd B, Landsberg D, Rush D, Cole E. Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ. 2005;173(10):S1–25.
- Papalois VE, Moss A, Gillingham KJ, Sutherland DE, Matas AJ, Humar A. Pre-emptive transplants for patients with renal failure: an argument against waiting until dialysis. Transplantation. 2000;70(4):625–31.
- Pérez-Flores I, Sánchez-Fructuoso A, Calvo N, Marques M, Anaya S, Ridao N, Rodríguez A, Barrientos A. Preemptive kidney transplant from deceased donors: an advantage in relation to reduced waiting list. Transplant Proc. 2007;2007:2123–4 Elsevier.
- Ye H, Zhou Q, Fan L, Guo Q, Mao H, Huang F, Yu X, Yang X. The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients. BMC Nephrol. 2017;18:1–9.
- Kasiske BL, Snyder JJ, Matas AJ, Ellison MD, Gill JS, Kausz AT. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol. 2002;13(5):1358–64.
- 11. Liem YS, Weimar W. Early living-donor kidney transplantation: a review of the associated survival benefit. Transplantation. 2009;87(3):317–8.
- Auneau-Enjalbert L, Hardouin JB, Blanchin M, Giral M, Morelon E, Cassuto E, Meurette A, Sébille V. Comparison of longitudinal quality of life outcomes in preemptive and dialyzed patients on waiting list for kidney transplantation. Qual Life Res. 2020;29(4):959–70.
- Huang Y, Samaniego M. Preemptive kidney transplantation: has it come of age? Nephrol Ther. 2012;8(6):428–32.
- Dinavahi R, Akalin E. Preemptive kidney transplantation in patients with diabetes mellitus. Endocrinol Metab Clin North Am. 2007;36(4):1039–49;
- Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med. 2006;354(10):997–9.
- 16. Renew JR, Pai SL. A simple protocol to improve safety and reduce cost in hemodialysis patients undergoing elective surgery. Middle East J Anaes-thesiol. 2014;22(5):487–92.
- Folsom AR, Lutsey PL, Astor BC, Wattanakit K, Heckbert SR, Cushman M. Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol Dial Transplant. 2010;25(10):3296–301.
- Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial. 2006;19(4):317–22.
- 19. Wang X, Shapiro JI. Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Nat Rev Nephrol. 2019;15(3):159–75.
- Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17(12):1321–60.
- Liang HY, Hsiao YL, Yeh HC, Ting IW, Lin CC, Chiang HY, Kuo CC. Associations between myocardial diastolic dysfunction and cardiovascular

mortality in chronic kidney disease: A large single-center cohort study. J Am Soc Echocardiogr. 2022;35(4):395–407.

- Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10(2):165–93.
- Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233–71.
- Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.
- Wesselink E, Kappen T, Torn H, Slooter A, Van Klei W. Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review. Br J Anaesth. 2018;121(4):706–21.
- Sessler DI, Bloomstone JA, Aronson S, Berry C, Gan TJ, Kellum JA, Plumb J, Mythen MG, Grocott MP, Edwards MR. Perioperative quality initiative consensus statement on intraoperative blood pressure, risk and outcomes for elective surgery. Br J Anaesth. 2019;122(5):563–74.
- D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265–81.
- Aytekin S, Dinç B, Ertuğ Z, Hadimioğlu N, Aytekin EÇ. Perioperative comparison of preemptive and non-preemptive renal transplant recipients. Turk J Anaesthesiol Reanim. 2020;48(2):102.
- Kovesdy CP. Metabolic acidosis and kidney disease: does bicarbonate therapy slow the progression of CKD? Nephrol Dial Transplant. 2012;27(8):3056–62.
- Kimmoun A, Novy E, Auchet T, Ducrocq N, Levy B. Hemodynamic consequences of severe lactic acidosis in shock states: from bench to bedside. Crit Care (London, England). 2015;19(1):175.
- Berger DS, Fellner SK, Robinson KA, Vlasica K, Godoy IE, Shroff SG. Disparate effects of three types of extracellular acidosis on left ventricular function. Am J Physiol. 1999;276(2):H582–594.
- Otter D, Austin C. Simultaneous monitoring of vascular contractility, intracellular pH and intracellular calcium in isolated rat mesenteric arteries; effects of weak bases. Exp Physiol. 2000;85(3):349–51.
- Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A, Asfar P, Perez P, Meziani F. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med. 2010;36(12):2019–29.
- 34. Jung B, Rimmele T, Le Goff C, Chanques G, Corne P, Jonquet O, Muller L, Lefrant JY, Guervilly C, Papazian L, et al. Severe metabolic or mixed acidemia on intensive care unit admission: incidence, prognosis and administration of buffer therapy. A prospective, multiple-center study. Crit Care (London, England). 2011;15(5):R238.
- Kimmoun A, Ducrocq N, Sennoun N, Issa K, Strub C, Escanyé JM, Leclerc S, Levy B. Efficient extra- and intracellular alkalinization improves cardiovascular functions in severe lactic acidosis induced by hemorrhagic shock. Anesthesiology. 2014;120(4):926–34.
- Yoo SW, Kwon OJ, Kang CM. Preemptive living-donor renal transplantation: outcome and clinical advantages. Transpl Proc. 2009;41(1):117–20.
- Joo KW, Shin SJ, Lee SH, Ha JW, Kim S, Kim YS. Preemptive transplantation and long-term outcome in living donor kidney transplantation, singlecenter experience. Transpl Proc. 2007;39(10):3061–4.
- Grams ME, Chen BP, Coresh J, Segev DL. Preemptive deceased donor kidney transplantation: considerations of equity and utility. Clin J Am Soc Nephrol. 2013;8(4):575–82.
- Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, Wang Z, Baird B, Barenbaum L, Cheung AK. Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant. 2005;20(1):167–75.
- Ishani A, Ibrahim HN, Gilbertson D, Collins AJ. The impact of residual renal function on graft and patient survival rates in recipients of preemptive renal transplants. Am J Kidney Dis. 2003;42(6):1275–82.
- 41. Abramowicz D, Hazzan M, Maggiore U, Peruzzi L, Cochat P, Oberbauer R, Haller MC, Van Biesen W. Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and

position statement by the Descartes Working Group and ERBP. Nephrol Dial Transplant. 2016;31(5):691–7.

- Sandid MS, Assi MA, Hall S. Intraoperative hypotension and prolonged operative time as risk factors for slow graft function in kidney transplant recipients. Clin Transplant. 2006;20(6):762–8.
- Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med. 2007;357(8):797–805.

## **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

